A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Tislelizumab (Primary) ; Dacarbazine; Doxorubicin; Vindesine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 20 Apr 2021 New trial record